Factories in space — manufacturing materials impossible on Earth, returned by hypersonic capsule
HQ: El Segundo, CA, United States | Founded: 2021 | Employees: ~300 (est.) | Stage: Late Stage VC ($1.58B valuation) | Website: https://www.varda.com
Varda Space Industries was founded in January 2021 by Will Bruey, a former SpaceX Dragon capsule engineer, and Delian Asparouhov, a Founders Fund partner, on a thesis that sounds like science fiction and has become logistics: some materials — especially pharmaceutical crystals — form better in microgravity, and the only way to industrialize that is to build factories in orbit and ship the product home. The enabling hardware is the reentry capsule: a blunt-body hypersonic vehicle that survives atmospheric reentry and lands cargo intact.
Execution has been relentless. W-1 (2023) proved the concept — growing ritonavir crystals in orbit and returning them despite an initial FAA/USAF reentry-permission denial that delayed landing; W-2 through W-4 followed, with W-4 spending nearly a full year in orbit before reentering January 2026; W-5 launched November 28, 2025 and reentered January 29, 2026 carrying a U.S. Navy payload — the company's first reentry of 2026 — and debuted Varda's vertically integrated satellite bus (previously built by Rocket Lab). Australia's Koonibba Test Range has become the primary recovery site.
The capsule capability spawned a defense business: in December 2024, the U.S. Air Force awarded Varda a $48M contract for hypersonic testbed services — using the capsule as a reusable instrumented hypersonic flight-test platform, a capability the Pentagon needs as it races China on hypersonics.
Capital tracks the dual-engine model: a $90M Series B (April 2024), a $187M Series C (July 2025), and a $251M Series D at a $1.58B valuation (February 2026) — $572M+ total, with Founders Fund, Khosla Ventures, a16z, and Pillar VC among backers.
Varda is the first company to make 'manufacturing in space' a shipping business: five missions flown, crystals grown in orbit, capsules landed, and a second business — hypersonic reentry testing — pulled out of the same hardware. The pivot logic is elegant: the reentry capsule built to return pharmaceutical crystals turned out to be exactly what the Pentagon needs for hypersonic flight testing, converting R&D burn into a $48M government revenue line while the pharma market matures. Founders Fund DNA (Asparouhov) plus SpaceX execution DNA (Bruey) has attracted $572M+ and a $1.58B valuation. The open question is market depth: does orbital pharma crystallization become a real industry, or does Varda remain a defense-testbed company with a science side project? The dual-engine answer so far is 'both, deliberately.'
Browse: Home | Blog | About | All Startups A-Z | View full profile on StartupWiki